Telix Pharmaceuticals (TLX) Limited Receives Transitional Pass-Through payment status for Gozellix

Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 23, Telix Pharmaceuticals Limited (NASDAQ:TLX) announced that the US Centers for Medicare & Medicaid Services had granted Transitional Pass-Through payment status for Gozellix. Gozellix is the company’s next-generation PSMA-PET imaging agent for prostate cancer.

The Transitional Pass-Through payment status means that hospitals will get separate reimbursement for using Gozellix starting October 1, 2025. Gozellix is a kit used to prepare gallium-68 Gozetotide for PET scans that helps detect PSMA-positive lesions in men with prostate cancer, especially those suspected of metastasis or biochemical recurrence.

Moreover, it has also been assigned a permanent HCPCS Level II code A9616, allowing recognition by CMS and commercial insurers for reimbursement starting October 1, 2025.

Telix Pharmaceuticals Limited (NASDAQ:TLX) is a biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals.

While we acknowledge the potential of TLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.